- Home
- IRTC vs IFRX Comparison
IRTC vs IFRX Comparison
Compare IRTC & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRTC
- IFRX
- Stock Information
- Founded
- IRTC 2006
- IFRX 2007
- Country
- IRTC United States
- IFRX Germany
- Employees
- IRTC N/A
- IFRX 66
- Industry
- IRTC Medical/Dental Instruments
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- IRTC Health Care
- IFRX Health Care
- Exchange
- IRTC Nasdaq
- IFRX Nasdaq
- Market Cap
- IRTC N/A
- IFRX 120.1M
- IPO Year
- IRTC 2016
- IFRX 2017
- Fundamental
- Price
- IRTC $74.29
- IFRX $2.08
- Analyst Decision
- IRTC Strong Buy
- IFRX Strong Buy
- Analyst Count
- IRTC 9
- IFRX 1
- Target Price
- IRTC $107.78
- IFRX $8.00
- AVG Volume (30 Days)
- IRTC 588.7K
- IFRX 250.6K
- Earning Date
- IRTC 10-30-2024
- IFRX 11-08-2024
- Dividend Yield
- IRTC N/A
- IFRX N/A
- EPS Growth
- IRTC N/A
- IFRX N/A
- EPS
- IRTC N/A
- IFRX N/A
- Revenue
- IRTC $560,025,000.00
- IFRX $187,930.00
- Revenue This Year
- IRTC $21.02
- IFRX $311.47
- Revenue Next Year
- IRTC $16.27
- IFRX $227.11
- P/E Ratio
- IRTC N/A
- IFRX N/A
- Revenue Growth
- IRTC 18.45
- IFRX 177.12
- 52 Week Low
- IRTC $55.92
- IFRX $1.17
- 52 Week High
- IRTC $124.12
- IFRX $2.44
- Technical
- Relative Strength Index (RSI)
- IRTC 43.22
- IFRX 67.08
- Support Level
- IRTC $72.36
- IFRX $1.51
- Resistance Level
- IRTC $90.19
- IFRX $2.15
- Average True Range (ATR)
- IRTC 3.97
- IFRX 0.23
- MACD
- IRTC -1.79
- IFRX 0.05
- Stochastic Oscillator
- IRTC 5.88
- IFRX 59.90
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.